Times Top News

Times Top News

Rossari Biotech sets up new R&D facility at Navi Mumbai

Rossari Biotech sets up new R&D facility at Navi Mumbai

by | Apr 27, 2026 | Share Market


Last Updated : Apr 27 2026 | 7:50 PM IST

The board of Rossari Biotech at its meeting held on 27 April 2026 has approved the relocation and shifting of the Company’s existing Research and Development Facility located at IIT Bombay to Ellora Olearise, A-786, 06th Floor, Khairane MIDC, Koparkhairane, Navi Mumbai – 400
710.

The company has set up a new Research and Development Facility at Navi Mumbai located at Ellora Olearise, A-786, 06th Floor, Khairane MIDC, Koparkhairane, Navi Mumbai – 400 710.

 

Disclaimer: No Business Standard Journalist was involved in creation of this content

First Published: Apr 27 2026 | 7:50 PM IST



Source link

Rossari Biotech sets up new R&D facility at Navi Mumbai

Board of Global Health approves execution of BTA for 79-bed cancer care hospital

by | Apr 27, 2026 | Share Market


Last Updated : Apr 27 2026 | 7:50 PM IST

At meeting held on 27 April 2026

The board of Global Health at its meeting held today i.e. 27 April 2026, has inter alia, approved execution of a Business Transfer Agreement (BTA) for a 79 bedded Cancer Care Hospital in Indore, assignment of lease deed as part of the transaction and execution of fresh lease for an additional 1,700 sqft of the space within the facility. The target hospital is in close proximity to Company’s existing facility in Indore.

The hospital is strategically located just 500 meters from Medanta Indore existing facility and will enable seamless integration and operational synergies.

The target hospital has been purpose-built with a primary focus on cancer care.

 

The transaction will allow Medanta to further strengthen its presence in the region, enhance its portfolio of tertiary and quaternary care services, and fill the existing specialty gap in oncology.

Disclaimer: No Business Standard Journalist was involved in creation of this content

First Published: Apr 27 2026 | 7:50 PM IST



Source link

Rossari Biotech sets up new R&D facility at Navi Mumbai

Mahindra & Mahindra acquires additional 28.03% stake in Carnot Technologies

by | Apr 27, 2026 | Share Market


Last Updated : Apr 27 2026 | 7:50 PM IST

Mahindra & Mahindra has completed the execution of a share purchase agreement for acquisition of an additional 28.03% stake in Carnot Technologies from certain promoters of Carnot. Post completion of the transaction, the company’s holding in Carnot will increased to 80.72% of the paid-up equity share capital and collectively 89% in terms of voting rights. This increase in stake is in line with the Company’s belief in the long-term potential of precision farming and telematics technology.
Carnot would continue to be the subsidiary of the company.
 

Disclaimer: No Business Standard Journalist was involved in creation of this content

First Published: Apr 27 2026 | 7:50 PM IST



Source link

Rossari Biotech sets up new R&D facility at Navi Mumbai

Samvardhana Motherson International to indirectly hold 100% stake in Vacuform

by | Apr 27, 2026 | Share Market


Last Updated : Apr 27 2026 | 7:50 PM IST

The board of Samvardhana Motherson International (SAMIL) at its meeting held on 27 April 2026, inter-alia, considered and approved acquisition through its 100% step down subsidiary namely MSSL Global RSA Module Engineering (MSSL RSA) of 49% of equity share capital of Vacuform 2000 Proprietary (Vacuform) from the initial promoters of Vacuform, subject to satisfactory completion of conditions precedent.

Post completion of afore-mentioned acquisition, SAMIL will hold 100% of equity share capital of Vacuform via its wholly owned subsidiaries namely MSSL RSA and Motherson Global Investments B.V., Netherland in the ratio of 49% and 51%, respectively. Thereafter, Vacuform will become an indirect wholly owned subsidiary of SAMIL.

 

Vacuform is inter-alia engaged into the business of manufacturing of Vacuum forming and Blow Moulded parts for automotive customers and has presence in South Africa.

Disclaimer: No Business Standard Journalist was involved in creation of this content

First Published: Apr 27 2026 | 7:50 PM IST



Source link

Rossari Biotech sets up new R&D facility at Navi Mumbai

Surya Roshni secures export orders worth Rs 86 crore from USA

by | Apr 27, 2026 | Share Market


Last Updated : Apr 27 2026 | 7:04 PM IST

Surya Roshni has announced that it has bagged two export orders aggregating Rs 86 crore from the United States of America.

The first order, valued at Rs 68.11 crore, is for the supply of ERW steel and OCTG casing & tubing of API SCT grade, while the second order, worth Rs 17.89 crore, is for the supply of ERW carbon steel pipes of API SL grade. Both orders are export contracts from international entities (names not disclosed) and are to be executed by June 2026.

Surya Roshni, incorporated in 1973, has emerged as Indias largest ERW pipes exporter, largest GI pipes producer, and the second largest in the lighting segment. Its focus is on developing a value-added product mix (3LPE coated pipes and alkyd pipes).

 

The company’s consolidated net profit slipped 11.35% to Rs 79.69 crore in Q3 FY26 as against Rs 89.9 crore in Q3 FY25. However, revenue from operations rose 3.18% year on year to Rs 1,927.49 crore in Q3 FY26.

Shares of Surya Roshni rose 1.53% to close at Rs 238.80 on the BSE.

Disclaimer: No Business Standard Journalist was involved in creation of this content

First Published: Apr 27 2026 | 7:04 PM IST



Source link

YouTube
Instagram
WhatsApp